Lymphoma and myeloma patients, as well as their caregivers, will have the opportunity to interact with leading specialists in the field and learn of the latest developments in disease treatment and clinical research at a symposium set for Jan. 9 in Houston, Texas.
The event, “Lymphoma/Myeloma Update for Patients: What’s New for 2016?”, is being presented by The University of Texas MD Anderson Cancer Center and its sponsors include the Leukemia & Lymphoma Society, Patient Power and the Multiple Myeloma Opportunities for Research & Education (MORE). It takes place at the Omni Houston Westside, 13210 Katy Freeway.
Attendees will hear more on the latest research in lymphoma/myeloma and advice on best approaches to issues faced by patients and their caregivers. The event hopes to increase awareness of lymphoma/myeloma and of available clinical trial opportunities.
The seminar’s subject areas include:
- The latest in transplant therapy
- New treatment options for newly diagnosed and relapsed lymphoma/myeloma patients
- Clinical trial opportunities for lymphoma/myeloma patients
- Coping with chronic disease
Presenters will also discuss progress in treatments that include stem cell transplantation, CAR T-cells and other immunotherapies, as well as information on new multiple myeloma clinical trials.
“This is a tremendous opportunity for patients and their caregivers and families to hear from some of the top experts in all areas of treatment for lymphoma and myeloma,” Jatin Shah, MD, associate professor in the Department of Lymphoma/Myeloma at MD Anderson, said in a press release. “This event is designed to answer patients’ questions about the newest research and therapies for these diseases.”
The symposium begins at 7 a.m., with a myeloma session held from 8 a.m. to 12:30 p.m., followed by a session on lymphoma from 1 p.m. to 5 p.m.
Registration costs $20. For more information and to register for the event, click on www.mdanderson.org/conferences or call 713-745-6130. Participants with special needs are asked to call 866-849-5866.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?